Children’s Art Project at M. D. Anderson Cancer Center

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

For 27 years, the Children’s Art Project at the University of Texas M. D. Anderson Cancer Center has made life better for children with cancer. Each year, the project offers holiday, everyday, and Valentine collections of note cards and gift items.

For 27 years, the Children’s Art Project at the University of Texas M. D. Anderson Cancer Center has made life better for children with cancer. Each year, the project offers holiday, everyday, and Valentine collections of note cards and gift items. The line also includes gift bags, silk scarves, ties, sterling silver jewelry, and other items featuring the young patients’ imaginative artwork.

Proceeds from 1999 card and gift sales have funded a record $1.5 million in programs benefiting M. D. Anderson patients, including pediatric cancer research initiatives to improve the long-range outlooks for children with cancer. The project expects to top these figures for the 2000 season.

Thousands of community volunteers contribute their time and talents to the project year round. To produce the large amount of art involved, a record 48 designers participated in putting together this year’s holiday collection. Last year, over 12,000 volunteers donated more than 425,000 hours (the equivalent of 205 full-time employees) to the project.

Brighter Futures

“At the Children’s Art Project, we are proud to focus on making lives better for children with cancer,” said Shannan Murray, director of the project. “Their futures are important to us, and our goal is to enable these young patients to grow up as normally as possible, in spite of the fact that they face a monumental battle with cancer. We like to think that it’s partly because of the Children’s Art Project that M. D. Anderson’s pediatric patients have brighter futures.”

Products are available at retail outlets throughout the country, online, and through direct mail. For a free catalogue or to place an order, call 1-800-231-1580 or visit www.childrensart.org on the Web.

Recent Videos
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.